AbCellera Biologics Inc.
ABCL
10.70 EUR
1 Tag: N/A
Der Alarm wird direkt gespeichert, ohne auf die Homepage zu springen.
Kursalarme fuer ABCL
Bitte anmelden, um Kursalarme zu sehen und zu speichern.
Finanzen
Unternehmensinfo
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Aktuelle News
-
AbCellera Biologics (ABCL) Could Be 27% Undervalued As ABCL635 Data Draws Focus
Vorschau anzeigen
AbCellera Biologics (ABCL) drew fresh attention after disclosing it will present new Phase 1/2 data on its investigational antibody ABCL635 at The Menopause Society’s 2026 Annual Meeting. That clinical spotlight arrives after a sharp run, with AbCellera Biologics posting a 90 day share price return of 84.49% and a year to date share price gain of 265.74%. The 1 year total shareholder return of 126.85% points to strong recent momentum despite earlier long term volatility. Scan other health and...
-
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
Vorschau anzeigen
VANCOUVER, British Columbia, October 08, 2026--AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
-
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
Vorschau anzeigen
VANCOUVER, British Columbia, October 01, 2026--AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
-
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
Vorschau anzeigen
VANCOUVER, British Columbia, September 16, 2026--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
-
Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?
Vorschau anzeigen
On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will fund all research and development and retain commercialization rights. In return, […]